Valeant announces market availability of Oxsoralen-Ultra

ALISO VIEJO, Calif. Valeant Pharmaceuticals has made a treatment for psoriasis available again, following a shortage, the drug maker said Wednesday.

Valeant said Oxsoralen-Ultra (methoxsalen) capsules would be available on a limited supply basis. The company said it experienced a shortage of Oxsoralen products since last year due to an unanticipated change in the supplier of the drug’s active ingredient.

“Valeant understands the importance of Oxsoralen-Ultra to patients suffering from psoriasis, and we have been working diligently in partnership with the [Food and Drug Administration] to address the drug shortage,” Valeant COO specialty pharmaceuticals Rajiv De Silva said. “We are pleased to be able to begin re-supplying Oxsoralen-Ultra to physicians and their patients on a limited basis and apologize for any issues this shortage has caused.”